Guolla L, Breitbart S, Foroutan F, et al. Impact of vincristine-steroid pulses during maintenance for B-cell pediatric ALL: a systematic review and meta-analysis. Blood. 2023;141(24):2944-2954.

Multi-drug frontline chemotherapy regimens, tested and refined via pediatric oncology cooperative group clinical trials over the past five decades, have increased survival rates among children and adolescents/young adults (AYAs) with B-acute lymphoblastic leukemia (B-ALL), which now exceed 90% (Figure).1,2  In North America, current curative regimens comprise more intensive induction and post-induction phases lasting approximately nine months and a less intensive, but nonetheless essential, maintenance phase lasting approximately 18 months. Clinical and laboratory characteristics such as age and white blood cell count at diagnosis, involvement of the central nervous system and other extramedullary sites, leukemia-associated genetic alterations, and responses to initial chemotherapy based upon assessments of minimal/measurable residual disease have been used to support risk-adapted intensification (and de-intensification) of therapy when appropriate.3-6 

Figure

Overall survival of children with ALL treated on legacy and contemporary Children’s Oncology Group clinical trials. Data are courtesy of the COG ALL committee and adapted from Raetz et al. Pediatric Blood & Cancer, 2023.15 

Figure

Overall survival of children with ALL treated on legacy and contemporary Children’s Oncology Group clinical trials. Data are courtesy of the COG ALL committee and adapted from Raetz et al. Pediatric Blood & Cancer, 2023.15 

Close modal

Essential components of maintenance therapy include daily oral 6-mercaptopurine (~75 mg/m2) and weekly oral methotrexate (~20 mg/m2), with monthly doses titrated based upon hematologic and hepatic laboratory parameters. Recent studies by the Children’s Oncology Group (COG) have demonstrated that adherence to >95% of prescribed 6-mercaptopurine therapy is critical for minimizing the risk of relapse in pediatric and AYA patients with newly diagnosed B-ALL.7,8  Additional studies have shown that 6-mercaptopurine adherence and relapse risk may also be differentially influenced by age, race/ethnicity, socioeconomic status, and other demographic factors.9,10 

In legacy frontline studies conducted during the 1980s, inclusion of intravenous vincristine and oral dexamethasone or prednisone “pulses” during 6-mercaptopurine/methotrexate-based maintenance therapy appreciably improved event-free survival (EFS) rates among pediatric patients with ALL.11  However, more recent trials focused on risk-adapted intensifcation of treatment following the induction phase have not detected a benefit of maintenance pulses in most patients with ALL (except those with IKZF1 deletions).12,13  As such, most modern ALL protocols in Europe do not include vincristine or steroid chemotherapy during the maintenance phase. In the recent COG AALL0932 phase III clinical trial, children with standard-risk B-ALL were randomized to receive vincristine/dexamethasone pulses every one versus three months during maintenance, which ultimately yielded no detectable differences in EFS.14  Results from AALL0932 have subsequently informed new treatment paradigms in North America with utilization of reduced-frequency pulses.

In their recent meta-analysis, Dr. Louise Guolla and colleagues extracted data from 25 studies published between 1965 and 2022 to assess the potential impact of vincristine/steroid maintenance pulses on EFS in pediatric patients (≤18 years old) with newly diagnosed B-ALL. Based on data from 12,513 patients, the authors ascertained that the clear benefit of maintenance pulses in historic trials (i.e., those conducted prior to the 1990s) was mitigated in more recent studies that employed a more intensive strategy for risk-adapted post-induction chemotherapy dosing prior to maintenance. Focused analysis of data from contemporary trials specifically demonstrated no deleterious impact of reduced-frequency vincristine/steroid pulses (or no pulses) on EFS, relapse risk, or overall surivival. Importantly, the inclusion of greater-frequency vincristine/steroid pulses was associated with increased toxicity, even in the historically less intensive maintenance phase of treatment, when patients and families often experience a more pronounced return to “normal life.” Adverse events assessed in the recent analysis included cytopenia, infection, osteonecrosis, and peripheral neuropathy; however, trends toward differences in toxicity were not always statistically ascertainable due to bias and/or wide confidence intervals given the heterogeneous datasets.

This large-scale meta-analysis focused upon the potential impact of maintenance vincristine/steroid pulses on relapse risk, survival, and therapy-associated adverse events in pediatric patients with B-ALL highlights the importance of clinical trial investigation and the success of modern risk-adapted therapies developed by international pediatric oncology consortia. These results will undoubtedly inform the design of future clinical trials, with a critical overarching goal of successful cure at less cost for pediatric and AYA patients with ALL.

Dr. Tasian indicated no relevant conflicts of interest.

1
Hunger
SP
,
Mullighan
CG
.
Acute lymphoblastic leukemia in children
.
N Engl J Med
.
2015
;
373
(
16
):
1541
1552
.
2
Inaba
H
,
Mullighan
CG
.
Pediatric acute lymphoblastic leukemia
.
Haematologica
.
2020
;
105
(
11
):
2524
2539
.
3
Smith
M
,
Arthur
D
,
Camitta
B
, et al
.
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia
.
J Clin Oncol
.
1996
;
14
(
1
):
18
24
.
4
Hunger
SP
,
Mullighan
CG
.
Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine
.
Blood
.
2015
;
125
(
26
):
3977
3987
.
5
Pieters
R
,
de Groot-Kruseman
H
,
Van der Velden
V
, et al
.
Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group
.
J Clin Oncol
.
2016
;
34
(
22
):
2591
2601
.
6
Schore
RJ
,
Angiolillo
AL
,
Kairalla
JA
, et al
.
Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: A report from COG AALL0932
.
Leukemia
.
2023
;
37
(
6
):
1375
1378
.
7
Bhatia
S
,
Landier
W
,
Shangguan
M
, et al
.
Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children’s oncology group
.
J Clin Oncol
.
2012
;
30
(
17
):
2094
2101
.
8
Landier
W
,
Hageman
L
,
Chen
Y
, et al
.
Mercaptopurine ingestion habits, red cell thioguanine nucleotide levels, and relapse risk in children with acute lymphoblastic leukemia: A report from the Children’s Oncology Group Study AALL03N1
.
J Clin Oncol
.
2017
;
35
(
15
):
1730
1736
.
9
Bhatia
S
,
Landier
W
,
Hageman
L
, et al
.
6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children’s Oncology Group study
.
Blood
.
2014
;
124
(
15
):
2345
2353
.
10
Wadhwa
A
,
Chen
Y
,
Hageman
L
, et al
.
Poverty and Relapse Risk in Children with Acute Lymphoblastic Leukemia: Children’s Oncology Group Study AALL03N1 Report
.
Blood
.
2023
.
11
Eden
T
,
Pieters
R
,
Richards
S
,
Childhood Acute Lymphoblastic Leukaemia Collaborative G
.
Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5,659 children
.
Br J Haematol
.
2010
;
149
(
5
):
722
733
.
12
Conter
V
,
Valsecchi
MG
,
Silvestri
D
, et al
.
Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial
.
Lancet
.
2007
;
369
(
9556
):
123
131
.
13
Clappier
E
,
Grardel
N
,
Bakkus
M
, et al
.
IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children’s Leukemia Group study 58951
.
Leukemia
.
2015
;
29
(
11
):
2154
2161
.
14
Angiolillo
AL
,
Schore
RJ
,
Kairalla
JA
, et al
.
Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children’s Oncology Group AALL0932
.
J Clin Oncol
.
2021
;
39
(
13
):
1437
1447
.
15
Raetz
EA
,
Bhojwani
D
,
Devidas
M
, et al
.
Children’s Oncology Group blueprint for research: Acute lymphoblastic leukemia
.
Pediatr Blood Cancer
.
2023
:
e30585
.